Raising Additional 290 Million Yen in Series A Funding Round
Raises Additional 290 Million Yen in Series A Funding Round
We are pleased to announce the successful closure of our additional Series A funding round, securing a substantial 290 million yen. This remarkable achievement is a testament to the unwavering support and belief in our mission to revolutionize animal health through cutting-edge oral vaccines.
At KAICO, we are on a mission to make a positive impact on the world by enhancing animal health and improving the productivity of livestock. Our business development strategy revolves around two crucial axes: the expansion of sales areas and countries, and the addition of target animals and pathogens.
Sales Area Expansion:
We are actively working towards establishing commercial distribution channels for our immune-enhancing feed additive for swine, set to launch in Vietnam initially. The goal is to seamlessly expand horizontally, reaching other countries predominantly in Asia. This strategic move aligns with our vision of creating a global footprint in the animal health sector.
Target Animals and Pathogens:
In our pursuit of excellence, we are focusing on developing oral vaccines for various infectious diseases in pigs. Additionally, we are pushing the boundaries with oral vaccines for aquaculture and pet animals, with each project advancing to the demonstration test phase. This multifaceted approach underscores our commitment to addressing diverse needs across the animal kingdom.
KAICO’s oral vaccines are not just a product; they represent a significant leap forward in animal health technology. Our innovative solutions will play a pivotal role in promoting the well-being of animals and enhancing the efficiency of livestock and aquaculture industries.